Authors

Latest:

Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer

An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.

Christopher Heery, MD

Latest:

Dr. Heery on Advancements in Treatment of Neuroendocrine Tumors

Dr. Christopher Heery, medical oncologist, National Cancer Institute, discusses the progress that has been made in the treatment of patients with neuroendocrine tumors.

Christopher J. Hoimes, DO

Latest:

Dr. Hoimes on EV-103 Results in Urothelial Cancer

Christopher J. Hoimes, DO, discusses the results of the EV-103 trial in patients with locally advanced or metastatic urothelial cancer.

Christopher J. Kane, MD

Latest:

Dr. Kane on Challenges Facing Genetic Testing in Prostate Cancer

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses challenges facing genetic testing for patients with prostate cancer.

Christopher J. Logothetis, MD

Latest:

Dr. Logothetis Discusses Prostate Cancer Therapy

Dr. Christopher Logothetis, from the MD Anderson Cancer Center, Discusses Prostate Cancer Therapy

Christopher J. Osik, A. A. R.T. (R)(T)

Latest:

Our Move to an EHR

The initial capital outlay for transitioning to an EHR is not small. In fact, cost is one of the main reasons practices have been slow to adopt EHRs.

Christopher J. Pietras, MD

Latest:

Dr. Pietras Discusses Pain Management in Ovarian Cancer

Christopher J. Pietras, MD, director, Palliative Care, assistant clinical professor, University of California, Los Angeles (UCLA) School of Medicine, discusses pain management in patients with ovarian cancer.

Christopher Lieu, MD

Latest:

Dr. Lieu Discusses the Focus of Future Research in mCRC

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses where future research should focus in metastatic colorectal cancer.

Christopher Lieu, MD, University of Colorado School of Medicine

Christopher P. Evans, MD

Latest:

Dr. Evans Discusses the Subgroup Analysis Results of the PREVAIL Study

Christopher P. Evans, MD, professor, chairman, Department of Urology, University of California at Davis School of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of an analysis of patients with and without visceral disease defined as liver and/or lung metastases who participated in the PREVAIL study.

Christopher P. Evans, MD, FACS, UC Davis

Christopher P. Filson, MD, MS

Latest:

New Imaging Strategies for Prostate Cancer Explored

Continuing research will have to evaluate whether combining serum biomarkers or other measurable clinical factors with multiparametric magnetic resonance imaging results can help make negative or inaccurate prostate biopsies a rarity rather than the norm.

Christopher Pietras, MD

Latest:

Dr. Pietras on Palliative Care for Patients With Ovarian Cancer

Christopher J. Pietras, MD, director, Palliative Care, assistant clinical professor, University of California, Los Angeles (UCLA) School of Medicine, discusses palliative care for patients with ovarian cancer.

Christopher R. Shea, MD

Latest:

Dr. Shea on Dermatological Management in Melanoma

Christopher R. Shea, MD, the Eugene J. Van Scott Professor of Medicine, chief of the Section of Dermatology at The University of Chicago Medicine, discusses the dermatological management of melanoma.

Christopher S. Seet, MD, PhD

Latest:

Dr. Seet on Aspects of Treatment Discontinuation in CML

Christopher S. Seet, MD, PhD, hematologist and oncologist, UCLA, discusses aspects of treatment discontinuation in chronic myeloid leukemia (CML).

Christopher Sweeney, MBBS

Latest:

Dr. Sweeney on the Phase III ENZAMET Trial in Metastatic Hormone-Sensitive Prostate Cancer

Christopher Sweeney, MBBS, medical oncologist at the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, discusses results of the phase III ENZAMET trial, which looked at standard therapy with or without enzalutamide as a treatment for patients with metastatic hormone-sensitive prostate cancer.

Christopher Sweeney, MBBS, Dana-Farber Cancer Institute

Christopher Twelves, MD

Latest:

Dr. Twelves Highlights Findings From the 2012 SABCS

Christopher Twelves, MD, Professor and Honorary Consultant in Medical Oncology, University of Leeds, highlights key findings from the 2012 San Antonio Breast Cancer Symposium, which took place in December 2012.

Christy A. Russell, MD, University of Southern California

Christy A. Russell, MD, USC Norris